EIF2AK4 and pulmonary arterial hypertension: It was reported that PVOD patients carrying biallelic EIF2AK4 mutations had a worse survival compared with IPAH patients [33] and PVOD patients without EIF2AK4 mutations [34], and showed no response to PAH therapy [34].